التفاصيل البيبلوغرافية
| العنوان: |
Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. |
| المؤلفون: |
Kang, Sung Hoon, Kim, Jeonghun, Kim, Jun Pyo, Cho, Soo Hyun, Choe, Yeong Sim, Jang, Hyemin, Kim, Hee Jin, Koh, Seong-Beom, Na, Duk L., Seong, Joon-Kyung, Seo, Sang Won |
| المصدر: |
European Journal of Nuclear Medicine & Molecular Imaging; Dec2021, Vol. 49 Issue 1, p321-330, 10p, 2 Diagrams, 1 Chart, 2 Graphs |
| مصطلحات موضوعية: |
AMYLOID, EMISSION-computed tomography, LIGANDS (Biochemistry), BIOLOGICAL tags, GLYCOPROTEINS |
| مستخلص: |
Purpose: In this study, we used machine learning to develop a new method derived from a ligand-independent amyloid (Aβ) positron emission tomography (PET) classifier to harmonise different Aβ ligands. Methods: We obtained 107 paired 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) PET images at the Samsung Medical Centre. To apply the method to FMM ligand, we transferred the previously developed FBB PET classifier to test similar features from the FMM PET images for application to FMM, which in turn developed a ligand-independent Aβ PET classifier. We explored the concordance rates of our classifier in detecting cortical and striatal Aβ positivity. We investigated the correlation of machine learning-based cortical tracer uptake (ML-CTU) values quantified by the classifier between FBB and FMM. Results: This classifier achieved high classification accuracy (area under the curve = 0.958) even with different Aβ PET ligands. In addition, the concordance rate of FBB and FMM using the classifier (87.5%) was good to excellent, which seemed to be higher than that in visual assessment (82.7%) and lower than that in standardised uptake value ratio cut-off categorisation (93.3%). FBB and FMM ML-CTU values were highly correlated with each other (R = 0.903). Conclusion: Our findings suggested that our novel classifier may harmonise FBB and FMM ligands in the clinical setting which in turn facilitate the biomarker-guided diagnosis and trials of anti-Aβ treatment in the research field. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Nuclear Medicine & Molecular Imaging is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
